Company intelligence / Profile preview

Nous Biosciences Inc.

Doylestown, Pennsylvania, United Statesnovusbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nous Biosciences, founded by Dr. Kunwar Shailubhai, recently received an SBIR grant from the National Cancer Institute to advance a new gastrointestinal drug. The company leverages discoveries around GC-C receptor signaling defects in GI diseases and has experience with nasal administration of antibodies, which has shown clinical benefit in related programs for multiple sclerosis at previous ventures[3]. Current programs are preclinical or early-stage.

Therapeutic areas: GastroenterologyOncology
Modalities: Monoclonal antibodiesPeptides
Industry: Biotech

Drug pipeline

1 asset

dolcanatide

Pre-clinical

Indications: Ulcerative colitis, Opioid-induced constipation

Beyond the preview

Go deeper on Nous Biosciences Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nous Biosciences Inc..

Explore the full profile